Seres Therapeutics (MCRB) Consolidated Net Income (2016 - 2025)
Historic Consolidated Net Income for Seres Therapeutics (MCRB) over the last 10 years, with Q3 2024 value amounting to $139.8 million.
- Seres Therapeutics' Consolidated Net Income rose 214431.93% to $139.8 million in Q3 2024 from the same period last year, while for Jun 2025 it was $139.8 million, marking a year-over-year increase of 61261.64%. This contributed to the annual value of $125.9 million for FY2024, which is 6478.68% up from last year.
- Per Seres Therapeutics' latest filing, its Consolidated Net Income stood at $139.8 million for Q3 2024, which was up 214431.93% from -$6.7 million recorded in Q2 2024.
- In the past 5 years, Seres Therapeutics' Consolidated Net Income ranged from a high of $139.8 million in Q3 2024 and a low of -$71.5 million during Q1 2023
- For the 5-year period, Seres Therapeutics' Consolidated Net Income averaged around -$13.1 million, with its median value being -$20.2 million (2020).
- As far as peak fluctuations go, Seres Therapeutics' Consolidated Net Income tumbled by 19726.9% in 2023, and later surged by 214431.93% in 2024.
- Quarter analysis of 5 years shows Seres Therapeutics' Consolidated Net Income stood at -$18.0 million in 2020, then crashed by 175.35% to -$49.7 million in 2021, then skyrocketed by 95.58% to -$2.2 million in 2022, then tumbled by 197.27% to -$6.5 million in 2023, then soared by 2240.73% to $139.8 million in 2024.
- Its last three reported values are $139.8 million in Q3 2024, -$6.7 million for Q2 2024, and -$7.2 million during Q1 2024.